Targeting mTOR for cancer treatment

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The mammalian target of rapamycin (mTOR) pathway regulates cellular growth and proliferation.
• Aberrant mTOR signaling is implicated in human cancers, making it a key therapeutic target.
• Rapamycin and its analogs exhibit significant antitumor effects in preclinical cancer models.

Purpose of the Study:

• To review the mTOR pathway's role in cancer and its potential as a drug target.
• To discuss current mTOR inhibitors in clinical development.
• To highlight challenges in developing mTOR inhibitors for cancer therapy.

Main Methods:

• Review of existing literature on mTOR pathway, inhibitors, and clinical trials.
• Analysis of preclinical and clinical data regarding mTOR inhibitor efficacy and safety.
• Discussion of pharmacodynamic assessments and predictive marker development.

Main Results:

• mTOR inhibitors have shown antitumor activity in various refractory cancers.
• These inhibitors are generally well-tolerated, complicating dose selection for clinical trials.
• Pharmacodynamic assessments in surrogate tissues are used, but interpatient variability is high.

Conclusions:

• mTOR inhibitors represent a promising class of anticancer drugs.
• Improved patient selection through predictive markers is crucial for clinical success.
• Further clinical studies are necessary to fully realize the therapeutic potential of mTOR inhibitors.